Skip to main content

Donation to Inflammatory diseases

Karolinska Institutet has received from the pharmaceutical company Meda
a donation of 35 million SEK (5.5 MUSD) for research in inflammatory diseases.

Inflammation is not merely part of our normal immune defence against microbes. Abnormal chronic inflammation underlies a number of our most common severe diseases such as rheumatic diseases, multiple sclerosis and psoriasis. Inflammation is also a hallmark of asthma and allergy. All these diseases are due to inflammation that has gone astray, which eventually causes destruction of vital organs such as the brain, joints or lungs.
Harmful inflammatory reactions are caused by an interaction between environmental factors and our genes. The challenge is to learn how genes and the environment interact to trigger the immune system’s destructive behaviour, and to use this knowledge both to change the environment (prevent disease) and to reprogram the immune system (treat the disease early and effectively).
”Inflammatory diseases constitute one of Meda’s prioritised therapy areas, says Anders Lönner, CEO of Meda. We are convinced that in the future it will be possible to both prevent and cure these diseases. Karolinska Institutet will play a decisive role in achieving this goal through its cutting-edge research on inflammatory diseases, new initiatives aimed at prevention and early treatment, as well as its unique proximity between clinical care and basic research.
A detailed plan for the donation will be developed together with the donors.

About the donor:
Meda is a leading specialty pharma company with a turnover of 8 billion SEK. Meda covers all of Europe and the US via its subsidiaries and has more than 2500 employees in development, production and marketing.
Meda's prioritised therapy areas are asthma/allergy, pain and inflammation, gastroen-terology, cardiology, and dermatology.